Home Cart Sign in  
Chemical Structure| 330784-47-9 Chemical Structure| 330784-47-9

Structure of Avanafil
CAS No.: 330784-47-9

Chemical Structure| 330784-47-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Avanafil is a potent and highly selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 of 5.2 nM for erectile dysfunction, exhibiting lower selectivity against PDE1, PDE6, and PDE11.

Synonyms: TA1790

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Avanafil

CAS No. :330784-47-9
Formula : C23H26ClN7O3
M.W : 483.95
SMILES Code : O=C(C1=CN=C(N2[C@H](CO)CCC2)N=C1NCC3=CC=C(OC)C(Cl)=C3)NCC4=NC=CC=N4
Synonyms :
TA1790
MDL No. :MFCD11977961
InChI Key :WEAJZXNPAWBCOA-INIZCTEOSA-N
Pubchem ID :9869929

Safety of Avanafil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Avanafil (TA-1790) exhibits strong and specific inhibitory effects on phosphodiesterase-5 (PDE-5), with IC50 values being 5.2 nM for PDE-5 and progressively higher for PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2, and PDE-1. It enhances the NO/cGMP/PKG signaling pathway, leading to a reduction in bone mineral density (BMD) loss, bone weakening, and oxidative stress. By preventing the breakdown of cyclic guanosine monophosphate (cGMP), Avanafil elevates cGMP levels, making it a candidate for studies on erectile dysfunction and osteoporosis[1][2][3].
Target
  • PDE5

    PDE5, IC50:1 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01095601 Healthy PHASE1 COMPLETED 2025-05-10 -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.07mL

0.41mL

0.21mL

10.33mL

2.07mL

1.03mL

20.66mL

4.13mL

2.07mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories